Organogenesis Holdings Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Organogenesis Holdings heeft een totaal eigen vermogen van $263.5M en een totale schuld van $63.5M, wat de schuld-eigenvermogensverhouding op 24.1% brengt. De totale activa en totale passiva bedragen respectievelijk $443.2M en $179.7M. De EBIT Organogenesis Holdings is $13.9M waardoor de rentedekking 6.7 is. Het heeft contanten en kortetermijnbeleggingen van $89.9M.
Belangrijke informatie
24.1%
Verhouding schuld/eigen vermogen
US$63.49m
Schuld
| Rente dekkingsratio | 6.7x |
| Contant | US$89.90m |
| Aandelen | US$263.50m |
| Totaal verplichtingen | US$179.66m |
| Totaal activa | US$443.16m |
Recente financiële gezondheidsupdates
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Recent updates
Organogenesis: Lurking Disruption With Recovery To Follow
Oct 15Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Sep 09We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 15Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Jun 10Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
May 21Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
May 01Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Apr 10These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Jan 04Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
May 31Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?
Jan 19Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio
Oct 18Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Sep 23Organogenesis gets FDA clearance for PuraPly MZ for wound healing
Aug 15Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors
Jul 28Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly
Jun 10Organogenesis Holdings: What Now
May 18The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet
Mar 31These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well
Mar 04Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $234.2M ) ORGO } overtreffen de korte termijn passiva ( $85.7M ).
Langlopende schulden: De kortetermijnactiva ORGO ( $234.2M ) overtreffen de langetermijnschulden ( $93.9M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ORGO heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van ORGO is de afgelopen 5 jaar gedaald van 315.3% naar 24.1%.
Schuldendekking: De schuld van ORGO wordt goed gedekt door de operationele kasstroom ( 34.5% ).
Rentedekking: De rentebetalingen op de schuld van ORGO worden goed gedekt door EBIT ( 6.7 x dekking).